Lantheus Inc. (LNTH)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
92.63
-2.02 (-2.13%)
At close: Jan 14, 2025, 3:59 PM
Lantheus Inc. Revenue Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DEFINITY Revenue | 76.97M | 78.10M | 76.56M | 67.34M | 70.53M | 68.82M | 63.62M | 60.74M | 62.31M | 58.33M | 59.31M | 57.64M | 59.84M | 55.97M | 56.79M | 527.00K | 576.00K | 569.00K | 562.00K |
DEFINITY Revenue Growth | -1.45% | +2.01% | +13.70% | -4.53% | +2.48% | +8.18% | +4.74% | -2.51% | +6.82% | -1.66% | +2.91% | -3.69% | +6.92% | -1.44% | +10676.28% | -8.51% | +1.23% | +1.25% | n/a |
License and Royalty Revenues Revenue | 4.13M | 1.33M | 662.00K | 438.00K | 7.62M | 8.53M | 7.29M | 5.93M | 5.94M | 28.87M | 6.76M | 5.39M | 7.50M | 5.19M | 23.10M | n/a | n/a | n/a | n/a |
License and Royalty Revenues Revenue Growth | +209.59% | +101.66% | +51.14% | -94.25% | -10.69% | +17.06% | +22.93% | -0.25% | -79.42% | +326.77% | +25.39% | -28.09% | +44.55% | -77.53% | n/a | n/a | n/a | n/a | n/a |
Other Precision Diagnostics Revenue | 6.28M | 5.83M | 5.93M | 5.74M | 5.45M | 5.81M | 6.02M | 6.17M | 5.36M | 5.26M | 5.68M | 7.56M | 6.74M | 6.98M | n/a | n/a | n/a | n/a | n/a |
Other Precision Diagnostics Revenue Growth | +7.85% | -1.80% | +3.34% | +5.24% | -6.08% | -3.57% | -2.48% | +15.14% | +1.86% | -7.37% | -24.84% | +12.18% | -3.47% | n/a | n/a | n/a | n/a | n/a | n/a |
PYLARIFY Revenue | 259.76M | 273.25M | 258.87M | 215.43M | 210.52M | 195.47M | 160.64M | 143.75M | 130.23M | 92.78M | 35.68M | 96.68M | 93.56M | 87.32M | n/a | n/a | n/a | n/a | n/a |
PYLARIFY Revenue Growth | -4.94% | +5.56% | +20.17% | +2.33% | +7.70% | +21.68% | +11.75% | +10.38% | +40.37% | +160.00% | -63.09% | +3.33% | +7.15% | n/a | n/a | n/a | n/a | n/a | n/a |
Product Revenue | 374.60M | 392.76M | 369.31M | 319.51M | 314.08M | 292.26M | 161.56M | 233.37M | 217.78M | 180.01M | 6.84M | 8.89M | 2.81M | 1.50M | n/a | n/a | n/a | n/a | n/a |
Product Revenue Growth | -4.62% | +6.35% | +15.59% | +1.73% | +7.47% | +80.90% | -30.77% | +7.16% | +20.98% | +2530.94% | -23.04% | +216.15% | +87.47% | n/a | n/a | n/a | n/a | n/a | n/a |
Radiopharmaceutical Oncology Revenue | 259.76M | 273.25M | 259.25M | 216.28M | 211.34M | 196.19M | 7.24M | 144.68M | 131.16M | 94.10M | 22.04M | 5.30M | 7.90M | 5.25M | n/a | n/a | n/a | n/a | n/a |
Radiopharmaceutical Oncology Revenue Growth | -4.94% | +5.40% | +19.87% | +2.34% | +7.72% | +2610.14% | -95.00% | +10.31% | +39.38% | +326.95% | +315.55% | -32.83% | +50.29% | n/a | n/a | n/a | n/a | n/a | n/a |
Strategic Partnerships And Other Revenue | 15.25M | 8.72M | 6.51M | 7.32M | 12.78M | 8.98M | 24.73M | 5.60M | 5.45M | 28.58M | 87.04M | 22.68M | 23.77M | 22.80M | n/a | n/a | n/a | n/a | n/a |
Strategic Partnerships And Other Revenue Growth | +74.80% | +34.00% | -11.08% | -42.72% | +42.35% | -63.68% | +341.44% | +2.70% | -80.92% | -67.17% | +283.76% | -4.59% | +4.26% | n/a | n/a | n/a | n/a | n/a | n/a |
Techne Lite Revenue | 20.48M | 28.19M | 21.71M | 23.27M | 21.59M | 20.99M | 94.37M | 22.09M | 19.44M | 22.61M | n/a | 87.88M | 90.36M | 85.75M | n/a | n/a | n/a | n/a | n/a |
Techne Lite Revenue Growth | -27.34% | +29.81% | -6.69% | +7.77% | +2.90% | -77.76% | +327.11% | +13.65% | -14.00% | n/a | n/a | -2.74% | +5.37% | n/a | n/a | n/a | n/a | n/a | n/a |
Total Precision Diagnostics Revenue | 103.73M | 112.11M | 104.21M | 96.35M | 97.58M | 95.62M | n/a | 89.01M | 87.11M | 86.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Precision Diagnostics Revenue Growth | -7.48% | +7.58% | +8.16% | -1.26% | +2.05% | n/a | n/a | +2.18% | +1.06% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
Quarter | Dec 31, 2020 | Dec 31, 2019 |
---|---|---|
Us Segment Revenue | 294.80M | 72.53M |
Us Segment Revenue Growth | +306.42% | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 84.23M | 92.54M | 93.44M | 75.56M | 73.14M | 62.61M | 55.89M | 66.62M | 49.17M | 60.09M | 57.94M | 81.95M | 45.74M | 60.81M | 30.31M | 26.54M | 29.83M | 26.98M | 26.83M | 27.69M | 28.21M | 24.24M | 22.99M | 22.35M | 24.09M | 23.70M | 23.18M | 24.72M | 22.15M | 22.81M | 22.48M | 18.68M | 18.80M | 19.08M | 18.82M | 17.93M | 17.84M | 24.67M | 18.20M |
Selling, General, and Administrative Revenue Growth | -8.98% | -0.96% | +23.67% | +3.31% | +16.82% | +12.02% | -16.11% | +35.48% | -18.17% | +3.71% | -29.30% | +79.15% | -24.77% | +100.61% | +14.20% | -11.01% | +10.57% | +0.54% | -3.12% | -1.84% | +16.38% | +5.46% | +2.84% | -7.21% | +1.61% | +2.25% | -6.20% | +11.58% | -2.87% | +1.43% | +20.39% | -0.64% | -1.49% | +1.39% | +4.98% | +0.49% | -27.70% | +35.60% | n/a |
Research and Development Revenue | 24.15M | 60.60M | 48.02M | 16.82M | 14.45M | 15.90M | 30.53M | 272.23M | 12.52M | 14.73M | 12.20M | 11.29M | 11.25M | 12.06M | 10.36M | 12.64M | 11.68M | 4.42M | 4.05M | 4.43M | 4.86M | 5.79M | 4.93M | 4.55M | 4.32M | 4.21M | 3.99M | 3.98M | 3.55M | 5.24M | 5.35M | 3.71M | 2.85M | 2.61M | 3.04M | 3.07M | 2.46M | 2.64M | 6.20M |
Research and Development Revenue Growth | -60.15% | +26.19% | +185.45% | +16.43% | -9.13% | -47.92% | -88.78% | +2074.85% | -15.05% | +20.75% | +8.06% | +0.36% | -6.71% | +16.42% | -18.03% | +8.17% | +164.46% | +9.14% | -8.71% | -8.77% | -16.13% | +17.57% | +8.31% | +5.44% | +2.40% | +5.67% | +0.33% | +11.87% | -32.23% | -2.00% | +44.23% | +30.22% | +9.24% | -14.10% | -0.98% | +24.74% | -6.82% | -57.42% | n/a |
Sales and Marketing Revenue | 43.72M | 45.03M | 45.55M | 35.26M | 37.40M | 36.46M | 32.62M | 26.98M | 25.41M | 27.49M | 20.35M | 19.42M | 17.20M | 17.63M | 14.17M | 12.86M | 11.61M | 6.30M | 10.13M | 10.39M | 10.15M | 10.95M | 10.40M | 9.91M | 10.48M | 12.13M | 10.64M | 10.42M | 10.07M | 11.60M | 10.21M | 8.69M | 8.71M | 9.84M | 9.31M | 7.81M | 8.63M | 9.23M | 9.07M |
Sales and Marketing Revenue Growth | -2.92% | -1.12% | +29.16% | -5.71% | +2.59% | +11.77% | +20.88% | +6.17% | -7.56% | +35.07% | +4.79% | +12.96% | -2.47% | +24.40% | +10.24% | +10.75% | +84.12% | -37.76% | -2.52% | +2.37% | -7.28% | +5.30% | +4.90% | -5.41% | -13.62% | +14.00% | +2.08% | +3.45% | -13.17% | +13.60% | +17.59% | -0.23% | -11.55% | +5.76% | +19.23% | -9.58% | -6.46% | +1.73% | n/a |